Clearmind Medicine (NASDAQ:CMND) Announces Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMNDGet Free Report) issued its earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, Zacks reports.

Clearmind Medicine Trading Up 0.9 %

Shares of CMND stock opened at $1.14 on Friday. The stock has a market capitalization of $4.86 million, a PE ratio of -0.61 and a beta of 1.02. Clearmind Medicine has a 1-year low of $0.95 and a 1-year high of $2.30. The business has a 50-day moving average of $1.35 and a 200 day moving average of $1.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.72.

Clearmind Medicine Company Profile

(Get Free Report)

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.

Featured Stories

Earnings History for Clearmind Medicine (NASDAQ:CMND)

Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.